Abstract

The nonclinical safety profile of the 5-HT4 partial agonist, PF-04995274, supported clinical development for symptomatic treatment of Alzheimer's disease

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call